RenovoRx Q1 2023 net loss $3.3M; Phase III data shows 60% survival benefit

RenovoRx, Inc.

2024-Q1 EPS reported -$0.36

Cash and equivalents were $3.7M at March 31, 2023; net loss $3.3M vs $3.0M in Q1 2022.
Phase III TIGeR-PaC interim analysis: 60% survival benefit, >65% reduction in side effects vs systemic chemo.
Closed $5M registered direct offering subsequent to quarter end.
Appointed Robert J. Spiegel (former CMO of Schering-Plough) to Board; Leesa Gentry as SVP Clinical Operations.
Issued 8th U.S. patent extending RenovoTAMP therapy platform IP coverage.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

RenovoRx, Inc. reported the first quarter ended March 31, 2023 results: net income $3.3 million.

Period: the first quarter ended March 31, 2023
Net income: $3.3 million
Result: reported results

Exact text from the filing

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of cancers, today announced financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

RenovoRx, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016947

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.